CN112057605A - Marine collagen oligopeptide and preparation method thereof - Google Patents
Marine collagen oligopeptide and preparation method thereof Download PDFInfo
- Publication number
- CN112057605A CN112057605A CN202010978659.XA CN202010978659A CN112057605A CN 112057605 A CN112057605 A CN 112057605A CN 202010978659 A CN202010978659 A CN 202010978659A CN 112057605 A CN112057605 A CN 112057605A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- stirring
- collagen oligopeptide
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 33
- 108010035532 Collagen Proteins 0.000 title claims abstract description 33
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 33
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 33
- 229920001436 collagen Polymers 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 235000014441 Prunus serotina Nutrition 0.000 claims abstract description 19
- 241001412173 Rubus canescens Species 0.000 claims abstract description 19
- 240000008042 Zea mays Species 0.000 claims abstract description 17
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 17
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 17
- 235000005822 corn Nutrition 0.000 claims abstract description 17
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 14
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 14
- 108010028690 Fish Proteins Proteins 0.000 claims abstract description 14
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 14
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 14
- 235000005805 Prunus cerasus Nutrition 0.000 claims abstract description 14
- 244000207449 Prunus puddum Species 0.000 claims abstract description 14
- 235000009226 Prunus puddum Nutrition 0.000 claims abstract description 14
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 14
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 14
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 14
- 239000008367 deionised water Substances 0.000 claims abstract description 14
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 14
- 239000001509 sodium citrate Substances 0.000 claims abstract description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 14
- 229940013618 stevioside Drugs 0.000 claims abstract description 14
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019202 steviosides Nutrition 0.000 claims abstract description 14
- 235000013976 turmeric Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004320 sodium erythorbate Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000012258 stirred mixture Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 42
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 31
- 229940116269 uric acid Drugs 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 238000009423 ventilation Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 201000005569 Gout Diseases 0.000 description 15
- 108010093894 Xanthine oxidase Proteins 0.000 description 12
- 102100033220 Xanthine oxidase Human genes 0.000 description 12
- 230000001603 reducing effect Effects 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium erythorbate Chemical compound [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A marine collagen oligopeptide and its preparation method are provided. The invention relates to marine collagen oligopeptide, which comprises the following raw materials in parts by weight: 60-80 parts of marine fish protein peptide, 10-20 parts of celery powder, 5-8 parts of black cherry powder, 5-10 parts of turmeric powder, 3-8 parts of moringa leaf powder, 1-5 parts of chitosan oligosaccharide, 4-5 parts of corn stigma powder, 1-3 parts of sour cherry concentrated juice, 0.5-1 part of sodium citrate, 0.2-0.3 part of D-sodium erythorbate, 0.1-0.5 part of stevioside, 0.4-1 part of sodium carboxymethylcellulose and 200 parts of deionized water 150-doped materials. The preparation method disclosed by the invention is simple, high in weighing precision, pure in taste, fine and soft in taste, and has the unique aromatic smell of the corn stigma and extremely high nutritional value, and can effectively relieve ventilation, effectively inhibit the increase of blood uric acid value, reduce the synthesis of uric acid and protect the kidney.
Description
Technical Field
The invention particularly relates to marine collagen oligopeptide and a preparation method thereof.
Background
Gout is a very ancient disease, accompanied by the whole process of human civilization development, and uric acid kidney stones have been found in egyptian mummification over 7000 years of the earth; in the early years, gout is mostly seen in people at the upper layers of society, such as those who reach sense and are honored and young, so that gout is also called as 'rich disease'; with the development of social economy, the dietary structure and the life style of people are changed, the aging of population is more and more obvious, the prevalence rate of gout is gradually increased, and the incidence of gout is found to be younger in recent years.
Gout is a metabolic disease caused by purine metabolic disorder, continuously increased blood uric acid concentration and deposition of urate crystals on soft tissues. The gout is characterized by hyperuricemia, recurrent acute arthritis, chronic nodular swelling, chronic interstitial nephritis and renal calculus caused by kidney involvement and the like clinically.
Hyperuricemia is the most important biochemical basis for gout, and urate crystal deposition is the result of hyperuricemia with a significant positive correlation between gout incidence and blood uric acid levels.
At present, anti-inflammation, promotion of uric acid excretion and inhibition of xanthine oxidase activity are the most important means in gout treatment. Anti-inflammatory and analgesic drugs, which can treat symptoms and root causes but only relieve pain caused by excessive uric acid and can not reduce the content of uric acid in human body; allopurinol has obvious effect of reducing uric acid, but uric acid quickly rises after the allopurinol is stopped, the side effect is large, more O2 is generated, and the allopurinol has toxicity to liver and bone marrow and needs to be taken in a small dose. The development of safe and effective uric acid-reducing and anti-gout drugs is imperative.
Disclosure of Invention
The invention aims to provide marine collagen oligopeptide and a preparation method thereof, and aims to solve the technical problems in the prior art.
In order to achieve the purpose, the invention provides the following technical scheme: the marine collagen oligopeptide comprises the following raw materials in parts by weight: 60-80 parts of marine fish protein peptide, 10-20 parts of celery powder, 5-8 parts of black cherry powder, 5-10 parts of turmeric powder, 3-8 parts of moringa leaf powder, 1-5 parts of chitosan oligosaccharide, 4-5 parts of corn stigma powder, 1-3 parts of sour cherry concentrated juice, 0.5-1 part of sodium citrate, 0.2-0.3 part of D-sodium erythorbate, 0.1-0.5 part of stevioside, 0.4-1 part of sodium carboxymethylcellulose and 200 parts of deionized water 150-doped materials.
Preferably, the preparation method comprises the following steps:
(1) adding a certain amount of deionized water into a homogenizer in an environment of a 10 ten thousand grade clean area, raising the temperature to be more than or equal to 50 ℃, and then starting homogenizing at the speed of 30 HZ; adding sodium carboxymethylcellulose into homogenizer, homogenizing for 5min until completely gelatinizing, and heating to 80 + -3 deg.C;
(2) adding marine fish protein peptide, celery powder and corn stigma powder into a crushing stirrer according to a certain proportion at room temperature for crushing and stirring, wherein the stirring speed is 100r/min, and the stirring time is 2-3 min; adding black cherry powder, turmeric powder, moringa oleifera leaf powder and chitosan oligosaccharide into the black cherry powder, stirring for 1-2min, sequentially adding a certain proportion of sour cherry concentrated juice, sodium citrate, D-sodium erythorbate and stevioside, stirring at the speed of 120r/min, and sieving the uniformly stirred mixture through a 10-mesh sieve to obtain a mixture A;
(3) putting the mixed material A obtained in the step (2) into a homogenizer for stirring, and starting homogenizing, wherein the homogenizing time is set to be 4-8min, the speed is 30HZ, the temperature is kept at 80 +/-3 ℃, and the holding time is 30-35 min; after the operation is finished, adjusting the temperature to 40 +/-5 ℃, cooling, keeping the temperature for 8-12min, filtering the mixture through a 100-mesh screen, and filling to obtain a mixture B;
(4) sterilizing the filling mixture B in the step (3) at 105 +/-3 ℃ in the environment of a general production area, and keeping the time for 30 min; putting the mixture into a dryer for drying at 125-135 ℃ for 1-2min, externally packaging the dried product, inspecting the finished product and putting the product in storage to obtain the final product.
Preferably, the weighing precision of the marine fish protein peptide, the celery powder, the black cherry powder, the turmeric powder, the moringa leaf powder, the chitosan oligosaccharide, the corn stigma powder, the sour cherry concentrated juice, the sodium citrate, the D-sodium erythorbate, the stevioside, the sodium carboxymethylcellulose and the deionized water is kept within +/-1%.
Description of the drawings:
FIG. 1: xanthine oxidase hydrolysis system process;
FIG. 2: a liquid phase separation effect diagram of the components of the xanthine metabolic system;
FIG. 3: the inhibition rate of marine collagen oligopeptide (uric acid-reducing peptide) on xanthine oxidase;
FIG. 4: effect of anti-uricopeptide on weight change in rats;
FIG. 5: the uric acid reducing activity of marine collagen oligopeptide (uric acid reducing peptide) in a rat body;
FIG. 6: the influence of marine collagen oligopeptide (uric acid-reducing peptide) on the content of creatinine and urea nitrogen in mouse serum;
FIG. 7: the effect of marine collagen oligopeptide (noruric acid peptide) on ADA and XOD activity in rat serum and liver;
FIG. 8: effect of marine collagen oligopeptides (noruric acid peptides) on ADA and xodrmrna expression in hepatocytes. Compared with the prior art, the invention has the beneficial effects that:
the preparation method disclosed by the invention is simple, high in weighing precision, pure in taste, fine and soft in mouthfeel, has the unique aromatic smell of corn stigma, has extremely high nutritional value, can effectively relieve ventilation, effectively inhibit the rise of blood uric acid value, and effectively reduce the mRNA expression quantity of Xanthine Oxidase (XOD) and adenosine transaminase (ADA), so that the synthesis of uric acid is reduced, serum creatinine and urea nitrogen are reduced, the kidney is protected, and no obvious toxic or side effect exists.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to table 1 and fig. 1 to 8 in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Example one
The marine collagen oligopeptide comprises the following raw materials in parts by weight: 60 parts of marine fish protein peptide, 20 parts of celery powder, 5 parts of black cherry powder, 10 parts of turmeric powder, 3 parts of moringa oleifera leaf powder, 5 parts of chitosan oligosaccharide, 4 parts of corn stigma powder, 3 parts of sour cherry concentrated juice, 0.5 part of sodium citrate, 0.3 part of D-sodium erythorbate, 0.1 part of stevioside, 1 part of sodium carboxymethylcellulose and 150 parts of deionized water. Preferably, the preparation method comprises the following steps:
(1) adding a certain amount of deionized water into a homogenizer in an environment of a 10 ten thousand grade clean area, raising the temperature to be more than or equal to 50 ℃, and then starting homogenizing at the speed of 30 HZ; adding sodium carboxymethylcellulose into homogenizer, homogenizing for 5min until completely gelatinizing, and heating to 80 + -3 deg.C;
(2) adding marine fish protein peptide, celery powder and corn stigma powder into a crushing stirrer according to a certain proportion at room temperature for crushing and stirring, wherein the stirring speed is 100r/min, and the stirring time is 2 min; adding black cherry powder, turmeric powder, moringa oleifera leaf powder and chitosan oligosaccharide into the black cherry powder, stirring for 2min, sequentially adding a certain proportion of sour cherry concentrated juice, sodium citrate, D-sodium erythorbate and stevioside, stirring at the speed of 120r/min, and sieving the uniformly stirred mixture through a 10-mesh sieve to obtain a mixture A;
(3) putting the mixed material A obtained in the step (2) into a homogenizer for stirring, starting homogenizing, setting the homogenizing time to be 4min, setting the speed to be 30HZ, keeping the temperature to be 80 +/-3 ℃, and keeping the temperature for 35 min; after the operation is finished, adjusting the temperature to 40 +/-5 ℃, cooling, keeping the temperature for 8min, filtering the mixture through a 100-mesh screen, and filling to obtain a mixture B;
(4) sterilizing the filling mixture B in the step (3) at 105 +/-3 ℃ in the environment of a general production area, and keeping the time for 30 min; putting the mixture into a dryer for drying at 135 ℃ for 1min, externally packaging the dried product, inspecting the finished product and putting the finished product in storage to obtain the final product.
Example two
The marine collagen oligopeptide comprises the following raw materials in parts by weight: 80 parts of marine fish protein peptide, 10 parts of celery powder, 8 parts of black cherry powder, 5 parts of turmeric powder, 8 parts of moringa oleifera leaf powder, 1 part of chitosan oligosaccharide, 5 parts of corn stigma powder, 1 part of sour cherry concentrated juice, 1 part of sodium citrate, 0.2 part of D-sodium erythorbate, 0.5 part of stevioside, 0.4 part of sodium carboxymethylcellulose and 200 parts of deionized water.
Preferably, the preparation method comprises the following steps:
(1) adding a certain amount of deionized water into a homogenizer in an environment of a 10 ten thousand grade clean area, raising the temperature to be more than or equal to 50 ℃, and then starting homogenizing at the speed of 30 HZ; adding sodium carboxymethylcellulose into homogenizer, homogenizing for 5min until completely gelatinizing, and heating to 80 + -3 deg.C;
(2) adding marine fish protein peptide, celery powder and corn stigma powder into a crushing stirrer according to a certain proportion at room temperature for crushing and stirring, wherein the stirring speed is 100r/min, and the stirring time is 3 min; adding black cherry powder, turmeric powder, moringa oleifera leaf powder and chitosan oligosaccharide into the black cherry powder, stirring for 1min, sequentially adding a certain proportion of sour cherry concentrated juice, sodium citrate, D-sodium erythorbate and stevioside, stirring at the speed of 120r/min, and sieving the uniformly stirred mixture through a 10-mesh sieve to obtain a mixture A;
(3) putting the mixed material A obtained in the step (2) into a homogenizer for stirring, starting homogenizing, setting the homogenizing time to be 8min, setting the speed to be 30HZ, keeping the temperature to be 80 +/-3 ℃, and keeping the temperature for 30 min; after the operation is finished, adjusting the temperature to 40 +/-5 ℃, cooling, keeping the temperature for 12min, filtering the mixture through a 100-mesh screen, and filling to obtain a mixture B;
(4) sterilizing the filling mixture B in the step (3) at 105 +/-3 ℃ in the environment of a general production area, and keeping the time for 30 min; drying in a dryer at 125 deg.C for 2min, packaging, inspecting, and storing to obtain final product.
EXAMPLE III
The marine collagen oligopeptide comprises the following raw materials in parts by weight: 75 parts of marine fish protein peptide, 18 parts of celery powder, 6 parts of black cherry powder, 7 parts of turmeric powder, 5 parts of moringa oleifera leaf powder, 3 parts of chitosan oligosaccharide, 4.6 parts of corn stigma powder, 2 parts of sour cherry concentrated juice, 0.7 part of sodium citrate, 0.3 part of D-sodium erythorbate, 0.3 part of stevioside, 0.7 part of sodium carboxymethylcellulose and 180 parts of deionized water. Preferably, the preparation method comprises the following steps:
(1) adding a certain amount of deionized water into a homogenizer in an environment of a 10 ten thousand grade clean area, raising the temperature to be more than or equal to 50 ℃, and then starting homogenizing at the speed of 30 HZ; adding sodium carboxymethylcellulose into homogenizer, homogenizing for 5min until completely gelatinizing, and heating to 80 + -3 deg.C;
(2) adding marine fish protein peptide, celery powder and corn stigma powder into a crushing stirrer according to a certain proportion at room temperature for crushing and stirring, wherein the stirring speed is 100r/min, and the stirring time is 3 min; adding black cherry powder, turmeric powder, moringa oleifera leaf powder and chitosan oligosaccharide into the black cherry powder, stirring for 2min, sequentially adding a certain proportion of sour cherry concentrated juice, sodium citrate, D-sodium erythorbate and stevioside, stirring at the speed of 120r/min, and sieving the uniformly stirred mixture through a 10-mesh sieve to obtain a mixture A;
(3) putting the mixed material A obtained in the step (2) into a homogenizer for stirring, starting homogenizing, setting the homogenizing time to be 5min, setting the speed to be 30HZ, keeping the temperature to be 80 +/-3 ℃, and keeping the temperature for 30 min; after the operation is finished, adjusting the temperature to 40 +/-5 ℃, cooling, keeping the temperature for 10min, filtering the mixture through a 100-mesh screen, and filling to obtain a mixture B;
(4) sterilizing the filling mixture B in the step (3) at 105 +/-3 ℃ in the environment of a general production area, and keeping the time for 30 min; putting the mixture into a dryer for drying at 130 ℃ for 2min, externally packaging the dried product, inspecting the finished product and putting the product into a warehouse to obtain the final product.
In the first to third embodiments, the weighing precision of the marine fish protein peptide, the celery powder, the black cherry powder, the turmeric powder, the moringa oleifera leaf powder, the chitosan oligosaccharide, the corn stigma powder, the sour cherry concentrated juice, the sodium citrate, the sodium D-isoascorbate, the stevioside, the sodium carboxymethylcellulose and the deionized water is kept within +/-1%.
In the above embodiment, the third embodiment is the best embodiment, not only has pure taste and fine and soft mouthfeel, has the specific aromatic smell of the corn stigma, but also has extremely high nutritional value, can effectively relieve ventilation, effectively inhibit the rise of blood uric acid value, reduce the synthesis of uric acid, and protect the kidney.
According to the third preferred embodiment, the marine collagen oligopeptide (the uric acid lowering peptide)) is tested in vitro, in a rat body and on a human body, and the specific test data are as follows:
1. in vitro Activity of Marine collagen oligopeptide (uric acid lowering peptide))
The production of uric acid is inhibited by inhibiting the activity of Xanthine Oxidase (XOD), a key enzyme in purine metabolism.
As can be seen from fig. 1-3: the marine collagen oligopeptide (uric acid-reducing peptide) has obvious effect of inhibiting xanthine activity, the inhibition rate is increased along with the increase of the concentration of the marine collagen oligopeptide (uric acid-reducing peptide), and when the concentration of the marine collagen oligopeptide (uric acid-reducing peptide) is 4%, the inhibition rate is almost equal to the inhibition effect of 0.5% allopurinol.
2. Activity of marine collagen oligopeptide (noruric acid peptide) in rat body
(1) Establishing and grouping animal models: SD rats are adaptively fed for 1 week in an environment with standard temperature of 22-25 ℃ and humidity of 40-60%, and then are randomly divided into a normal group and an experimental group. The rats in the blank group were given ordinary feed, the rats in the experimental group were given high-purine injection, and the rats were continuously fed for 10 weeks under the same conditions. 1.5ml of blood was collected from orbital venous plexus, and the level of blood uric acid was measured with an assay kit. Compared with the normal group, the blood uric acid level of the experimental rat has obvious difference, namely the model building success.
(2) Grouping gastric lavage administration: the successful modeling experimental groups of SD rats were randomly divided into 6 groups. The groups are respectively a model group, an allopurin group, an anti-A high group, an anti-A low group, an anti-B high group and an anti-B low group, and each group is 8. After grouping, rats in the experimental group continued to be given high purine injections and began gavage administration once a day to rats in the normal group and experimental group (model group, group of individual purines, group of anti-a high, group of anti-a low, group of anti-B high, group of anti-B low). The doses of the model group drugs are shown in Table 1 and administered continuously for 30 days.
Table 1: rat dose setting
As can be seen from FIG. 4, there was no significant difference in body weight between the rats in each group, indicating that marine collagen oligopeptide (norurea peptide) has no significant toxic side effects on the rats.
As can be seen from FIG. 5, the two high-low dose groups of marine collagen oligopeptide (uric acid-lowering peptide) have obvious uric acid-lowering activity, wherein the low-dose group has stronger effect of lowering blood uric acid level.
As can be seen from fig. 6, both of the high and low dosages of the marine collagen oligopeptide (norurea peptide) can effectively reduce serum creatinine and urea nitrogen, and exhibit kidney protection efficacy.
As can be seen from fig. 7, each of the marine collagen oligopeptide (norurea peptide) groups had a certain inhibitory activity against Xanthine Oxidase (XOD) in rats, but had almost no inhibitory activity against adenosine transaminase (ADA). As can be seen from fig. 8, marine collagen oligopeptide (uric acid-lowering peptide) can effectively reduce the mRNA expression levels of Xanthine Oxidase (XOD) and adenosine transaminase (ADA), thereby reducing the synthesis of uric acid.
3. Uric acid reducing effect of marine collagen oligopeptide (uric acid reducing peptide) in human body
Daily oral dose: 1 g to 2 g
Oral cycle: 30-60 days
And (4) checking indexes: blood uric acid change, gout attack cycle, gout-related symptoms
The conclusion reached is: after one period (60 days) of oral administration, the blood uric acid value of most of trial population is basically recovered to the normal level (600+ umol/L is reduced to about 400 umol/L);
after oral administration for half a period (30 days), the joints of the trial population have obvious sensation;
after taking the medicine orally for a half period (30 days), people who try to eat seafood and the like to induce gout do not have gout symptoms any more;
after one period (60 days) of oral administration, the blood uric acid value of the marine collagen oligopeptide (the uric acid reducing peptide) gradually rises after half a year of stopping administration.
In conclusion, the traditional Chinese medicine composition has the advantages of well relieving gout symptoms, effectively inhibiting the increase of blood uric acid value, reducing the synthesis of uric acid and protecting the kidney, and has no side effect.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (3)
1. A marine collagen oligopeptide, which is characterized in that: the raw materials comprise the following components in parts by weight: 60-80 parts of marine fish protein peptide, 10-20 parts of celery powder, 5-8 parts of black cherry powder, 5-10 parts of turmeric powder, 3-8 parts of moringa leaf powder, 1-5 parts of chitosan oligosaccharide, 4-5 parts of corn stigma powder, 1-3 parts of sour cherry concentrated juice, 0.5-1 part of sodium citrate, 0.2-0.3 part of D-sodium erythorbate, 0.1-0.5 part of stevioside, 0.4-1 part of sodium carboxymethylcellulose and 200 parts of deionized water 150-doped materials.
2. The method for preparing marine collagen oligopeptide according to claim 1, wherein the marine collagen oligopeptide comprises: the method comprises the following steps:
(1) adding a certain amount of deionized water into a homogenizer in an environment of a 10 ten thousand grade clean area, raising the temperature to be more than or equal to 50 ℃, and then starting homogenizing at the speed of 30 HZ; adding sodium carboxymethylcellulose into homogenizer, homogenizing for 5min until completely gelatinizing, and heating to 80 + -3 deg.C;
(2) adding marine fish protein peptide, celery powder and corn stigma powder into a crushing stirrer according to a certain proportion at room temperature for crushing and stirring, wherein the stirring speed is 100r/min, and the stirring time is 2-3 min; adding black cherry powder, turmeric powder, moringa oleifera leaf powder and chitosan oligosaccharide into the black cherry powder, stirring for 1-2min, sequentially adding a certain proportion of sour cherry concentrated juice, sodium citrate, D-sodium erythorbate and stevioside, stirring at the speed of 120r/min, and sieving the uniformly stirred mixture through a 10-mesh sieve to obtain a mixture A;
(3) putting the mixed material A obtained in the step (2) into a homogenizer for stirring, and starting homogenizing, wherein the homogenizing time is set to be 4-8min, the speed is 30HZ, the temperature is kept at 80 +/-3 ℃, and the holding time is 30-35 min; after the operation is finished, adjusting the temperature to 40 +/-5 ℃, cooling, keeping the temperature for 8-12min, filtering the mixture through a 100-mesh screen, and filling to obtain a mixture B;
(4) sterilizing the filling mixture B in the step (3) at 105 +/-3 ℃ in the environment of a general production area, and keeping the time for 30 min; putting the mixture into a dryer for drying at 125-135 ℃ for 1-2min, externally packaging the dried product, inspecting the finished product and putting the product in storage to obtain the final product.
3. The method for preparing marine collagen oligopeptide according to claim 2, wherein the marine collagen oligopeptide comprises: the weighing precision of the marine fish protein peptide, the celery powder, the black cherry powder, the turmeric powder, the moringa leaf powder, the chitosan oligosaccharide, the corn stigma powder, the sour cherry concentrated juice, the sodium citrate, the D-sodium isoascorbate, the stevioside, the sodium carboxymethylcellulose and the deionized water is kept within +/-1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010978659.XA CN112057605A (en) | 2020-09-17 | 2020-09-17 | Marine collagen oligopeptide and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010978659.XA CN112057605A (en) | 2020-09-17 | 2020-09-17 | Marine collagen oligopeptide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112057605A true CN112057605A (en) | 2020-12-11 |
Family
ID=73680660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010978659.XA Pending CN112057605A (en) | 2020-09-17 | 2020-09-17 | Marine collagen oligopeptide and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112057605A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112546052A (en) * | 2020-12-28 | 2021-03-26 | 青岛博智汇力生物科技有限公司 | Composition containing marine oligosaccharide for preventing and treating gout |
| CN113424895A (en) * | 2021-07-16 | 2021-09-24 | 安徽天凯生物科技有限公司 | Formula of tablet candy with function of assisting in reducing uric acid |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130136151A (en) * | 2012-06-04 | 2013-12-12 | 권태선 | Improving gout, reducing uric acid, solving hangover of functional fermented food and method for producing of the same, and kimchi, gochujang, doenjang, soy sauce produced thereof |
| CN108850366A (en) * | 2018-08-08 | 2018-11-23 | 广州宏韵医药科技股份有限公司 | A kind of alternative tea composition and preparation method thereof with anti-trioxypurine effect |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
| CN111588042A (en) * | 2019-12-23 | 2020-08-28 | 上海赋康健康管理有限公司 | Dietary nutrition conditioning food for assisting in reducing uric acid and controlling gout |
-
2020
- 2020-09-17 CN CN202010978659.XA patent/CN112057605A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130136151A (en) * | 2012-06-04 | 2013-12-12 | 권태선 | Improving gout, reducing uric acid, solving hangover of functional fermented food and method for producing of the same, and kimchi, gochujang, doenjang, soy sauce produced thereof |
| CN108850366A (en) * | 2018-08-08 | 2018-11-23 | 广州宏韵医药科技股份有限公司 | A kind of alternative tea composition and preparation method thereof with anti-trioxypurine effect |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
| CN111588042A (en) * | 2019-12-23 | 2020-08-28 | 上海赋康健康管理有限公司 | Dietary nutrition conditioning food for assisting in reducing uric acid and controlling gout |
Non-Patent Citations (4)
| Title |
|---|
| 朱善元: "基础生物化学", vol. 1, 31 March 2007, 中国环境科学出版社, pages: 141 * |
| 林峰 等: "不同取材的食源性低聚肽嘌呤含量测定及其 在痛风患者营养治疗中的应用探讨", 食品与发酵工业, vol. 34, no. 10, pages 243 - 16 * |
| 薛耀明 等: "内分泌与代谢病学", vol. 1, 28 February 2018, 广东科技出版社, pages: 770 * |
| 郭花斌 等: "药食两用中草药在防治高尿酸血症上的研究进展", 世界最新医学信息文摘, vol. 18, no. 86, pages 50 - 53 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112546052A (en) * | 2020-12-28 | 2021-03-26 | 青岛博智汇力生物科技有限公司 | Composition containing marine oligosaccharide for preventing and treating gout |
| CN113424895A (en) * | 2021-07-16 | 2021-09-24 | 安徽天凯生物科技有限公司 | Formula of tablet candy with function of assisting in reducing uric acid |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112057605A (en) | Marine collagen oligopeptide and preparation method thereof | |
| US20190160136A1 (en) | Solid Beverage for Conditioning Qi Deficiency Constitution and Method for Producing the Same | |
| CN103142655B (en) | Composite probiotics for treating podagra and preparation method thereof | |
| CN105495258A (en) | Fruit beverage facilitating reduction of uric acid | |
| CN111887370A (en) | Uric acid-reducing ocean fish oligopeptide-chitosan oligosaccharide solid beverage | |
| CN110038119A (en) | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect | |
| CN112546052A (en) | Composition containing marine oligosaccharide for preventing and treating gout | |
| CN109620948A (en) | The full nature cell Opsonizing method of high lithemia/gout | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN110637909A (en) | Health tea for treating gout and preparation method thereof | |
| EP3574912B1 (en) | Composition for treating diabetic disease | |
| McMullen | Fructose increases uric acid contributing to metabolic syndrome-herbal, nutritional and dietary strategies to reduce uric acid | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| JP2002265365A (en) | Neutrophil function inhibitor | |
| CN104257676B (en) | One kind treats the migrainous compositionss of asthenic cold type | |
| CN1313112C (en) | Medicinal composition with nourishing and tranquilizing | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN116585379B (en) | Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout | |
| CN100391476C (en) | Medicine composition for delaying senility and raising immunity and its prepn | |
| CN111214476A (en) | Medicine composition for preventing and treating senile dementia | |
| JP2019108313A (en) | Composition for reducing in-blood urine acid values containing chitosan and ampelopsin | |
| CN106566759A (en) | Comprehensive ferment health care nutriment capable of delaying aging and improving human immunity and preparation method thereof | |
| Li | Synergistic antidepressant effect of Schisandra lignans and Schisandra polysaccharides | |
| CN117860851A (en) | Traditional Chinese medicine composition and pharmaceutical preparation for reducing blood uric acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |